Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
Robin Wilson, Matthijs G. Bossong, Elizabeth Appiah‐Kusi, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
María S. García‐Gutiérrez, Francisco Navarrete, Ani Gasparyan, et al.
Biomolecules (2020) Vol. 10, Iss. 11, pp. 1575-1575
Open Access | Times Cited: 211
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications
Ainhoa Bilbao, Rainer Spanagel
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 107
The therapeutic potential of purified cannabidiol
Saoirse E. O’Sullivan, Sanne Jensen, Gitte Nykjaer Nikolajsen, et al.
Journal of Cannabis Research (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 29
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Inga Dammann, Cathrin Rohleder, F. Markus Leweke
Pharmacopsychiatry (2024) Vol. 57, Iss. 03, pp. 115-132
Closed Access | Times Cited: 13
Cannabidiol and brain function: current knowledge and future perspectives
Moniek Schouten, Sebastiaan Dalle, Dante Mantini, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 8
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders
Olivier J. Manzoni, Antonia Manduca, Viviana Trezza
Trends in Pharmacological Sciences (2025)
Open Access | Times Cited: 1
Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence
Grace Blest‐Hopley, Marco Colizzi, Vincent Giampietro, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 66
The Impact of Cannabidiol on Human Brain Function: A Systematic Review
Albert Batalla, Julian Bos, Amber Postma, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 49
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Barbara Malinowska, Marta Baranowska‐Kuczko, Aleksandra Kicman, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1986-1986
Open Access | Times Cited: 46
The Impact of THC and CBD in Schizophrenia: A Systematic Review
Saeed Ahmed, Robert M. Roth, Corneliu N. Stanciu, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 46
Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
Marco Colizzi, Mirella Ruggeri, Sagnik Bhattacharyya
Frontiers in Psychology (2020) Vol. 11
Open Access | Times Cited: 49
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Edward Chesney, Dominic Oliver, Philip McGuire
Psychopharmacology (2021) Vol. 239, Iss. 5, pp. 1179-1190
Open Access | Times Cited: 32
The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder
Ruben van Boxel, Shiral S. Gangadin, Hella Janssen, et al.
Journal of Psychiatric Research (2023) Vol. 163, pp. 93-101
Open Access | Times Cited: 11
The neurobehavioural effects of cannabidiol in alcohol use disorder: study protocol for a double-blind, randomised, cross over, placebo-controlled trial
Tristan Hurzeler, Warren Logge, Joshua Watt, et al.
Contemporary Clinical Trials Communications (2024) Vol. 41, pp. 101341-101341
Open Access | Times Cited: 4
Cannabidiol attenuates precuneus activation during appetitive cue exposure in individuals with alcohol use disorder
Tristan Hurzeler, Warren Logge, Joshua Watt, et al.
European Archives of Psychiatry and Clinical Neuroscience (2025)
Open Access
A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
Cathy Davies, Robin Wilson, Elizabeth Appiah‐Kusi, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 32
Cannabidiol as a Treatment for Mood Disorders: A Systematic Review: Le cannabidiol comme traitement des troubles de l’humeur: une revue systématique
Jairo Vinícius Pinto, Gayatri Saraf, Christian Frysch, et al.
The Canadian Journal of Psychiatry (2019) Vol. 65, Iss. 4, pp. 213-227
Open Access | Times Cited: 31
Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies
J. M. H. Schoevers, Judith E. Leweke, F. Markus Leweke
Current Opinion in Psychiatry (2020) Vol. 33, Iss. 3, pp. 185-191
Closed Access | Times Cited: 30
Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment
Rebeca Pérez, Talita Glaser, Cecilia Villegas, et al.
Life (2022) Vol. 12, Iss. 12, pp. 2117-2117
Open Access | Times Cited: 16
Neuroimaging studies of cannabidiol and potential neurobiological mechanisms relevant for alcohol use disorders: a systematic review
Tristan Hurzeler, Joshua Watt, Warren Logge, et al.
Journal of Cannabis Research (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
Cássio Morais Loss, Lucas Teodoro, Gabriela Doná Rodrigues, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 23
Individual and combined effects of cannabidiol and Δ9-tetrahydrocannabinol on striato-cortical connectivity in the human brain
Matthew B. Wall, Tom P. Freeman, Chandni Hindocha, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 6, pp. 732-744
Open Access | Times Cited: 14
Cannabinoids, reward processing, and psychosis
Brandon Gunasekera, Kelly Diederen, Sagnik Bhattacharyya
Psychopharmacology (2021) Vol. 239, Iss. 5, pp. 1157-1177
Open Access | Times Cited: 19
Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway
Alexandre Vallée, Yves Lecarpentier, Jean-Noël Vallée
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 230-248
Closed Access | Times Cited: 16
Cannabidiol as an antipsychotic drug
Débora Cristina Niero Fabris, João Roberto Lisboa, Francisco Silveira Guimarães, et al.
International review of neurobiology (2024), pp. 295-317
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top